摘要 目的 基于TCGA数据库分析COL10A1在人表皮生长因子受体2(HER2）阳性乳腺癌患者中的表达及其与患者预后的关系。 方法 基于GEPIA、Oncomine数据库分析COL10A1在乳腺癌中的差异性表达，UALCAN数据库分析COL10A1在不同乳腺癌病理亚型中的表达差异。通过Kaplan-Meier Plotter数据库分析COL10A1与乳腺癌患者临床预后的关系。 结果 GEPIA、Oncomine等生物学数据库分析显示，乳腺癌组织中COL10A1 mRNA表达水平显著高于正常组织（P＜0.01）；HER2过表达型乳腺癌组织中COL10A1表达高于三阴型，差异有统计学意义（P＜0.05）。GEPIA和cBioPortal数据库分析显示，COL10A1与HER2 mRNA表达水平呈正相关（P＜0.01）。Kaplan-Meier Plotter在线数据库分析显示，HER2阳性乳腺癌组织中COL10A1高表达患者无复发生存率低（P＜0.01）。 结论 COL10A1在HER2阳性乳腺癌组织中呈高表达，并与患者预后呈负相关，有望成为HER2阳性乳腺癌患者药物治疗的一个潜在靶点。 Abstract：Objective To investigate the expression of COL10A1 in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer based on TCGA database and its association with prognosis. Methods The differential expression of COL10A1 in breast cancer was analyzed based on the GEPIA and Oncomine databases, and the UALCAN database was used to analyze the difference in the expression of COL10A1 in different subtypes of breast cancer. The Kaplan-Meier Plotter database was used to investigate the association between COL10A1 and clinical prognosis of breast cancer patients. Results The analysis based on the GEPIA and Oncomine biological databases showed that the mRNA expression of COL10A1 in breast cancer tissue was significantly higher than that in normal tissue (P<0.01), and the expression of COL10A1 in HER2-overexpressing breast cancer was significantly higher than that in triple-negative breast cancer (P<0.05). The GEPIA and cBioPortal databases showed a positive correlation between the mRNA expression of COL10A1 and HER2 (P<0.01). The Kaplan-Meier Plotter database analysis indicated that the patients with HER2-positive breast cancer and high expression of COL10A1 had a low relapse-free survival rate (P<0.01). Conclusion Through the in-depth searching of database oncogene information, it is proposed that COL10A1 is highly expressed in HER-positive breast cancer tissue and is negatively correlated with patient’s prognosis, and therefore, it may become a potential target for pharmacotherapy for HER-positive breast cancer
